Wall Street Zen Upgrades vTv Therapeutics (NASDAQ:VTVT) to “Hold”

vTv Therapeutics (NASDAQ:VTVT) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

VTVT has been the topic of a number of other research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of vTv Therapeutics in a research note on Monday, December 29th. BTIG Research reissued a “buy” rating and issued a $49.00 target price on shares of vTv Therapeutics in a research note on Wednesday. Roth Mkm started coverage on shares of vTv Therapeutics in a report on Thursday, January 22nd. They set a “buy” rating and a $58.00 target price on the stock. Evercore assumed coverage on shares of vTv Therapeutics in a research report on Thursday. They set an “outperform” rating and a $44.00 price target on the stock. Finally, TD Cowen initiated coverage on shares of vTv Therapeutics in a research note on Monday, January 5th. They issued a “buy” rating for the company. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $53.00.

vTv Therapeutics Stock Performance

NASDAQ:VTVT opened at $33.28 on Friday. The stock’s 50-day simple moving average is $35.93 and its 200 day simple moving average is $29.42. The company has a market cap of $131.12 million, a P/E ratio of -9.93 and a beta of 0.44. vTv Therapeutics has a 52-week low of $14.00 and a 52-week high of $44.00.

vTv Therapeutics (NASDAQ:VTVT) last issued its quarterly earnings results on Tuesday, March 10th. The biotechnology company reported ($0.58) EPS for the quarter, beating the consensus estimate of ($1.09) by $0.51. The company had revenue of ($0.02) million for the quarter.

Institutional Trading of vTv Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. bought a new stake in vTv Therapeutics in the 4th quarter valued at about $221,000. 683 Capital Management LLC bought a new position in shares of vTv Therapeutics during the fourth quarter worth approximately $731,000. Geode Capital Management LLC raised its position in shares of vTv Therapeutics by 84.3% in the fourth quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock valued at $1,128,000 after buying an additional 12,896 shares in the last quarter. Finally, Baker BROS. Advisors LP raised its position in shares of vTv Therapeutics by 52.4% in the third quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company’s stock valued at $3,463,000 after buying an additional 51,000 shares in the last quarter. Institutional investors and hedge funds own 17.51% of the company’s stock.

Trending Headlines about vTv Therapeutics

Here are the key news stories impacting vTv Therapeutics this week:

• Positive Sentiment: Evercore ISI initiated coverage with an “Outperform” recommendation, providing a new institutional buy-side endorsement that can attract demand and support the share price. Evercore initiation article
• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and $47 price target while raising several near-term EPS estimates (Q1–Q4 2026 and FY2026) and trimming losses for FY2027 relative to prior forecasts — a signal that the firm sees improving fundamentals in the nearer term and provides supportive analyst cover (no link available).
• Neutral Sentiment: vTv filed Q4 and full-year 2025 financial results and issued a corporate update; company results and commentary can influence sentiment depending on guidance and program milestones, so investors should review the release for pipeline/cash details. Q4/FY2025 results and corporate update
• Neutral Sentiment: Market calendars show vTv is projected to announce upcoming earnings — scheduled event risk can increase intraday volatility around the stock. Earnings projection article
• Negative Sentiment: Within the same HC Wainwright coverage notes, the firm lowered long‑range EPS assumptions (FY2028–FY2030 and FY2029 reductions), increasing projected longer-term losses. Those cuts could pressure expectations for longer-term profitability and cap upside despite near-term improvements (no link available).

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.